New Delhi: The All India Institute of Medical Sciences (AIIMS) Delhi will today start screening children for the clinical trials of Covaxin, the indigenous Covid-19 vaccine developed by Bharat Biotech and ICMR.
After getting permission from the Drugs Controller General of India (DCGI), AIIMS Delhi is now starting the screening process before starting the actual trials The DCGI’s approval came after a recommendation on 12 May by a Subject Expert Committee (SEC).
Experts have warned that a possible third wave can bring as much devastation as the second wave of the coronavirus pandemic if enough people are not vaccinated against the virus, and that children could be its prime target.
However, the vaccines being used in India – Covaxin, Covishield and Sputnik V – have not been approved for use on children.
